ARL4C and colorectal carcinoma: Mechanistically, ARL4C acted as a "central integrator," actively promoting both drug resistance and metastatic progression, establishing a cooperative model of "resistance plus metastasis." Our findings provide new insights into therapeutic resistance and recurrence in advanced CRC and highlight ARL4C as a promising target for clinical intervention.